Association between factor V Leiden mutation
and poor pregnancy outcomes among Palestinian women.
Individuals who are heterozygous for the Factor V Leiden mutation
carry a risk of venous thrombosis five to seven times higher than that of the general population; homozygous subjects have a risk 80 times higher.
The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation
and venous thrombosis.
Soy M, Tanriverdi K, Kocak R et al: Factor V leiden mutation
in Behcet's disease.
Our search for the Medline revealed a case report about an association of Factor V Leiden mutation
and lupus anticoagulant in a young man who developed lower extremity deep vein thrombosis (7).
Allele-specific genotype detection of factor V Leiden mutation
from polymerase chain reaction amplicons based on label-free electrochemical genosensor.
16) Since lupus anti coagulant may be a potential interferent in the modified assay, patients with lupus anticoagulant should be evaluated for the factor V Leiden mutation
by genetic testing.
The factor V Leiden mutation
is the most common genetic thrombophilia: the heterozygous form, found in 5%-8% of the normal population, increases the risk of VTE five-fold, whereas the rarer homozygous form confers an 18-fold risk increase.
The impact of the factor V leiden mutation
4-7) More than 95% of cases are due to a point mutation, known as the factor V Leiden mutation
, at 1 of the 3 arginine cleavage sites in the factor V gene.
Objectives: To determine the frequency of Protein C Protein S (PC and PS) antithrombin deficiency (AT III) and Factor V Leiden mutation
(FVL) as a cause of thrombophilia in the patients with venous thromboembolism (VTE) and cerebrovascular accident (CVA).
High prevalence of antithrombin III, protein C and protein S deficiency, but no factor V Leiden mutation
in venous thrombophilic Chinese patients in Taiwan.
11) Factor V Leiden mutation
, prothrombin gene mutation, and a deficiency of protein C, protein S, and antithrombin III have, taken together in two studies, been identified in more than 50% of cerebral ischemic strokes?
Women with the factor V Leiden mutation
who took COCs increased their risk of VTE compared with women with neither risk factor by 6.